

## PURSUIT OF ROBUST COMMERCIAL EXPANSION IN 2009

### TARGET: 6 TO 7 NEW LICENSES INCLUDING TWO COMMERCIAL LICENSES

**Nantes (France) – 13 January 2009** – Vivalis (NYSE Euronext Paris: VLS – ISIN: FR0004056851), a biopharmaceutical company that provides the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, announces its commercial targets and schedule for the publication of financial information for 2009.

#### 2009 commercial targets

Based on 2008's commercial successes with 7 new licenses that included 4 commercial licenses, Vivalis already anticipates the signature of 6 to 7 additional licenses in 2009 including two commercial licenses in the areas of vaccine production and therapeutic proteins.

Following a performance in 2008 marked by commercial, technological and regulatory successes, Vivalis continues to receive many expressions of interest by major worldwide laboratories to experiment and use its innovative EB66® technology platform.

In light of these new licenses, as well as its current portfolio of 21 licenses including 12 commercial license agreements, the revenues momentum since the 2008 third quarter is expected to continue over the coming quarters of 2009.

#### 2009 financial calendar

Event	Date * **
2008 annual revenue	Tuesday, 27 January 2009
2008 annual results	Tuesday, 31 March 2009
Presentation of 2008 annual results	Thursday, 1 April 2009, 5:30 p.m.
2009 first-quarter revenue	Wednesday, 29 April 2009
Annual General Meeting	Tuesday, 9 June 2009
2009 second-quarter revenue	Wednesday, 22 July 2009
2009 first-half results	Monday, 31 August 2009
2009 third-quarter revenue	Wednesday, 21 October 2009

\* Subject to modification.

\*\* Press releases are published after the close of trading.

\*\*\*\*\*

**Next press release:  
27 January 2009 (after the close of trading on Euronext Paris): 2008 annual revenue**

\*\*\*\*\*

**About Vivalis ([www.vivalis.com](http://www.vivalis.com))**

Vivalis (NYSE- Euronext: VLS) Vivalis (NYSE- Euronext: VLS) is a biopharmaceutical company that provides to the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs to prevent and treat viral diseases. Vivalis' know-how and proprietary technologies are commercially exploited in three main areas:

1. Vaccine development and manufacturing. Vivalis grants research and commercial licenses to its proprietary EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies and to the pharmaceutical industry for the production of viral vaccines.
2. Recombinant therapeutic protein and monoclonal antibody production systems development. Vivalis licenses to pharmaceutical and biotechnology companies its EBx® embryonic stem cell lines to manufacture recombinant therapeutic proteins. The company receives upfront and milestone fees and royalties on customer sales.
3. The build-up of a proprietary portfolio of vaccines and anti-viral molecules (Hepatitis C

Based in Nantes (France), Vivalis was created in 1999 by Group Grimaud (1,450 employees), the n°2 group worldwide in animal genetic breeding. Vivalis has established several partnerships with worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial, SAFC Biosciences. Vivalis is a member of the French Atlantic Biotherapies cluster.

**Vivalis**

Listed on Euronext Paris – Compartment C of NYSE Euronext  
Reuters: VLS.PA – Bloomberg: VLS FP  
**Included in NYSE Euronext's Next Biotech index**

**Investor Relations:**

**Vivalis**

Franck Grimaud, C.E.O.  
Email : [investors@vivalis.com](mailto:investors@vivalis.com)

**NewCap**

Financial Communications Agency  
Steve Grobet / Emmanuel Huynh  
Tel.: +33 (0) 1 44 71 94 91  
Email: [vivalis@newcap.fr](mailto:vivalis@newcap.fr)